Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis

NCT01711164 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT01711164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01711164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis
Lead sponsor
University Health Network, Toronto
Phase
Observational
Overall status
Completed
Start date
January 31, 2014
Completion date
September 30, 2016
Enrollment
106 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c infection